Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma

Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in pati...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2004-09, Vol.10 (18), p.6302S-6303S
Main Authors: Motzer, Robert J., Bacik, Jennifer, Mazumdar, Madhu
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c131S-f4f5a40e09159473c8c13a894a3d06773674ac1af78a548cec345ee1fa1cc66f3
cites cdi_FETCH-LOGICAL-c131S-f4f5a40e09159473c8c13a894a3d06773674ac1af78a548cec345ee1fa1cc66f3
container_end_page 6303S
container_issue 18
container_start_page 6302S
container_title Clinical cancer research
container_volume 10
creator Motzer, Robert J.
Bacik, Jennifer
Mazumdar, Madhu
description Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.
doi_str_mv 10.1158/1078-0432.CCR-040031
format article
fullrecord <record><control><sourceid>highwire_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1158_1078_0432_CCR_040031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_18_6302S</sourcerecordid><originalsourceid>FETCH-LOGICAL-c131S-f4f5a40e09159473c8c13a894a3d06773674ac1af78a548cec345ee1fa1cc66f3</originalsourceid><addsrcrecordid>eNo1kEFPwzAMhSMEYmPwDzjkjNQRN0mbHVHFYNIE0wpcIyska9DWoqRs4t-TMrjYT7afpfcRcg1sCiDVLbBSZUzwfFpV6yQY43BCxiBlmfG8kKdJ_5-MyEWMH4yBACbOyQikEIrlMCZPq9Bt2i723tA5mr4Lkbou0Por7P0et7RzdIW9t20f6cH3Da173Fi6eKNr26Z9ZbepYDC-7XZ4Sc4cbqO9-usT8jq_f6kes-Xzw6K6W2YGONSZE06iYJbNQM5EyY1Kc1QzgfydFWXJi1KgAXSlQimUsYYLaS04BGOKwvEJEce_JnQxBuv0Z_A7DN8amB7w6CG7HrLrhEcf8STbzdHW-E1z8MFqg62xIdhoU4Tm1610wVle8x8x92Rz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma</title><source>Freely Accessible Journals</source><creator>Motzer, Robert J. ; Bacik, Jennifer ; Mazumdar, Madhu</creator><creatorcontrib>Motzer, Robert J. ; Bacik, Jennifer ; Mazumdar, Madhu</creatorcontrib><description>Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-040031</identifier><identifier>PMID: 15448021</identifier><language>eng</language><publisher>American Association for Cancer Research</publisher><ispartof>Clinical cancer research, 2004-09, Vol.10 (18), p.6302S-6303S</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c131S-f4f5a40e09159473c8c13a894a3d06773674ac1af78a548cec345ee1fa1cc66f3</citedby><cites>FETCH-LOGICAL-c131S-f4f5a40e09159473c8c13a894a3d06773674ac1af78a548cec345ee1fa1cc66f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Motzer, Robert J.</creatorcontrib><creatorcontrib>Bacik, Jennifer</creatorcontrib><creatorcontrib>Mazumdar, Madhu</creatorcontrib><title>Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma</title><title>Clinical cancer research</title><description>Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.</description><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNo1kEFPwzAMhSMEYmPwDzjkjNQRN0mbHVHFYNIE0wpcIyska9DWoqRs4t-TMrjYT7afpfcRcg1sCiDVLbBSZUzwfFpV6yQY43BCxiBlmfG8kKdJ_5-MyEWMH4yBACbOyQikEIrlMCZPq9Bt2i723tA5mr4Lkbou0Por7P0et7RzdIW9t20f6cH3Da173Fi6eKNr26Z9ZbepYDC-7XZ4Sc4cbqO9-usT8jq_f6kes-Xzw6K6W2YGONSZE06iYJbNQM5EyY1Kc1QzgfydFWXJi1KgAXSlQimUsYYLaS04BGOKwvEJEce_JnQxBuv0Z_A7DN8amB7w6CG7HrLrhEcf8STbzdHW-E1z8MFqg62xIdhoU4Tm1610wVle8x8x92Rz</recordid><startdate>20040915</startdate><enddate>20040915</enddate><creator>Motzer, Robert J.</creator><creator>Bacik, Jennifer</creator><creator>Mazumdar, Madhu</creator><general>American Association for Cancer Research</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20040915</creationdate><title>Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma</title><author>Motzer, Robert J. ; Bacik, Jennifer ; Mazumdar, Madhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c131S-f4f5a40e09159473c8c13a894a3d06773674ac1af78a548cec345ee1fa1cc66f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Motzer, Robert J.</creatorcontrib><creatorcontrib>Bacik, Jennifer</creatorcontrib><creatorcontrib>Mazumdar, Madhu</creatorcontrib><collection>CrossRef</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Motzer, Robert J.</au><au>Bacik, Jennifer</au><au>Mazumdar, Madhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma</atitle><jtitle>Clinical cancer research</jtitle><date>2004-09-15</date><risdate>2004</risdate><volume>10</volume><issue>18</issue><spage>6302S</spage><epage>6303S</epage><pages>6302S-6303S</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.</abstract><pub>American Association for Cancer Research</pub><pmid>15448021</pmid><doi>10.1158/1078-0432.CCR-040031</doi></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2004-09, Vol.10 (18), p.6302S-6303S
issn 1078-0432
1557-3265
language eng
recordid cdi_crossref_primary_10_1158_1078_0432_CCR_040031
source Freely Accessible Journals
title Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T06%3A17%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-highwire_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Factors%20for%20Survival%20of%20Patients%20with%20Stage%20IV%20Renal%20Cell%20Carcinoma&rft.jtitle=Clinical%20cancer%20research&rft.au=Motzer,%20Robert%20J.&rft.date=2004-09-15&rft.volume=10&rft.issue=18&rft.spage=6302S&rft.epage=6303S&rft.pages=6302S-6303S&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-040031&rft_dat=%3Chighwire_cross%3E10_18_6302S%3C/highwire_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c131S-f4f5a40e09159473c8c13a894a3d06773674ac1af78a548cec345ee1fa1cc66f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/15448021&rfr_iscdi=true